MAGE-A3-specific memory T cell induction from healthy donors: a functional in vitro evaluation

Abstract

Aim:To determine whether PepTivator^® melanoma-associated antigen-A3 (MAGE-A3) primes early T-cell activation and memory skewing in human peripheral blood mononuclear cells (PBMCs).

Methods:PBMCs from 10 donors were stimulated with MAGE-A3 (manufacturer-recommended dose), negative control (NC), or CD3/CD28 and CytoStim™ (PC: positive control). Activation [CD69, CD25, HLA-DR (human leukocyte antigen-DR isotype)], proliferation, cytokines [24 h; GM-CSF (granulocyte-macrophage colony-stimulating factor), IFN-γ (interferon-gamma), IL-2 (interleukin-2), TNF-α (tumor necrosis factor-alpha)], and memory phenotypes (CD45RO/CD27 at days 0/7/14) were quantified by flow cytometry and MACSPlex. Paired statistics used repeated-measures models with Šidák correction; cytokines were analyzed on log10 scale.

Results:MAGE-A3 significantly increased early activation (CD69 ↑, CD25 ↑) and modestly increased proliferation, with selective IL-2/TNF-α rise and minimal IFN-γ and modest HLA-DR. Across two weeks, 6/10 donors showed increased central memory T cell (TCM)/effector memory T cell (TEM) with a corresponding decline in naïve cells relative to NC. Variability across donors was evident.

Conclusions:MAGE-A3 primes partial activation and memory skewing of human T cells in vitro, suggesting utility as a component antigen that likely benefits from professional antigen-presenting cell (APC) presentation and/or costimulation. We discuss limitations (single dose, in vitro context, donor variability) and implications for future dose-response, HLA-stratified, and APC-supported studies.

Keywords

MAGE-A3 / T lymphocytes / memory T cells / cytokines / immunotherapy / cancer antigen / adoptive cell therapy

References

[1] Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024; 93: 102693.

[2] Polanco D, Pinilla L, Gracia-Lavedan E, Mas A, Bertran S, Fierro G, et al. Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study. J Thorac Dis. 2021; 13: 1485-94.

[3] Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Martínez-Pérez A, Rodrigo JP, García-Pedrero JM, et al. Chemo-Immunotherapy: A New Trend in Cancer Treatment. Cancers (Basel). 2023; 15: 2912.

[4] Wu Y, Yuan M, Wang C, Chen Y, Zhang Y, Zhang J. T lymphocyte cell: A pivotal player in lung cancer. Front Immunol. 2023; 14: 1102778.

[5] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20: 651-68.

[6] Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023; 149: 8131-41.

[7] Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015; 7: 683-704.

[8] Khanna P, Blais N, Gaudreau P, Corrales-Rodriguez L. Immunotherapy Comes of Age in Lung Cancer. Clin Lung Cancer. 2017; 18: 13-22.

[9] Laban S, Giebel G, Klümper N, Schröck A, Doescher J, Spagnoli G, et al. MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget. 2017; 8: 14719-35.

[10] Telang G, Mishra S, Sureshbabu A, Kulkarni S, Joshi S, Singh R. MAGE-A3 as a target for cancer immunotherapy: A systematic review of clinical and preclinical evidence. Curr Probl Cancer. 2025; 58: 101237.

[11] Telang G, Mishra S, Sureshbabu A, Barage S, Kumar AWS, Singh R. Integrated in silico and experimental analysis identifies MAGE-A3, TRIM28, and HLA-A as immunomodulatory targets in lung cancer. Hum Gene. 2025; 46: 201492.

[12] Cibrián D, Sánchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017; 47: 946-53.

[13] Garcillán B, Megino RF, Herrero-Alonso M, Guardo AC, Perez-Flores V, Juraske C, et al. The role of the different CD3γ domains in TCR expression and signaling. Front Immunol. 2022; 13: 978658.

[14] Abbas AK. The Surprising Story of IL-2: From Experimental Models to Clinical Application. Am J Pathol. 2020; 190: 1776-81.

[15] Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine. 2018; 101: 14-8.

[16] Bajnok A, Ivanova M, Rigó J Jr, Toldi G. The Distribution of Activation Markers and Selectins on Peripheral T Lymphocytes in Preeclampsia. Mediators Inflamm. 2017; 2017: 8045161.

[17] Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014; 14: 24-35.

[18] Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 2001; 61: 4773-8.

[19] Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987; 139: 3802-7.

[20] Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, et al. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res. 2003; 63: 5587-94.

[21] Przybyla A, Zhang T, Li R, Roen DR, Mackiewicz A, Lehmann PV. Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8+ memory T cells can be detected in healthy humans. Cancer Immunol Immunother. 2019; 68: 709-20.